Brain waves: This Toronto startup is looking for the first signs of neurological disorders
By identifying biomarkers of brain disorders, Cove Neurosciences is working to speed up the development of new treatments.
Excerpt from the Press Release:
“We know that every patient is different. No two patients with dementia are the same,” says Toronto neurology resident and entrepreneur Nardin Samuel. And yet, she adds, they may end up with similar treatment plans — with varying results. By harnessing data and AI, Samuel is hoping to decode not only why conditions vary so widely between individuals but also why certain therapeutics might work for some people and not others.
At Cove Neurosciences, Samuel and co-founder Irene Harmsen have developed an advanced platform that analyzes brain imaging data from electroencephalography (EEG), magnetic resonance imaging (MRI) and magnetoencephalography (MEGs) from patients with various motor, mood and memory disorders. The aim, says Samuel, is to help researchers identify biomarkers associated with neurologic and psychiatric disorders, speed up clinical trials and pave the way for personalized treatment.
Mental health is a growing concern — it’s estimated one in five Canadians experience mental illness every year. How can data unlock our understanding of different disorders and potentially improve treatment?
If you think about something like depression, you give a patient a medication, and you say come back in four to six weeks and we’ll reassess.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?